Role of Sildenafil in delayed growth of Fetus

Not Applicable

• Conditions: Health Condition 1: O098- Supervision of other high risk pregnancies

• Registration Number: CTRI/2022/09/045582
• Lead Sponsor: Dr Robina Mirza

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. All pregnant women with single fetus with IUGR (Intrauterine Growth retardation)� � 

2.Patients with a regular menstrual pattern before

pregnancy� 

3.Patients willing to give informed consent

for the study and agreeing to follow up.� 

4.Early onset or Late onset I.U.G.R� 

5.Amniotic fluid index less than 10, pregnancy induced hypertension present / absent and booked cases.

Exclusion Criteria

1.Patient with uncertain gestational age

2. Patients with known or suspected fetal anomalies

3. Pregnancies with obstetrical complications (intrauterine infection, bleeding, premature rupture of membranes)

4. When urgent delivery is indicated in patient of end diastolic flow

5.Usage of any vasodilator medications like hydralazine, nitrates etc.

6.Multiple gestation (twin pregnancy, triplet pregnancy etc.)

7.Smokers, drug or alcohol abusers

8.Pregnant women less than 18 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The role of sildenafil in decreasing the poor perinatal outcomes expected in pregnancies with high vascular resistance in the uterine circulation (Birth Weight)Timepoint: At Birth

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes measured will be: <br/ ><br>1. UA Doppler indices. <br/ ><br>2. Maternal and fetal safety. <br/ ><br>3. GA at delivery. <br/ ><br>Timepoint: weekly